DRUG:CNSX
Bright Minds Biosciences Inc
CA$ ७५.७७
arrow_upward
+१.४७%(+१.१०) 1D
अक्टोबर १४, १०:५७:५३ GMT-४ · CAD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRUG...
Open
CA$ ७२.००
High
CA$ ७५.७७
Low
CA$ ७२.००
Mkt. cap
७४.७४ करोड
Avg. vol.
८४८.००
Volume
४०३.००
52-wk high
CA$ १७०.००
52-wk low
CA$ ६८.०२
EPS
-CA$ २.९०
No. of employees
२६
Open
CA$ ७२.००
High
CA$ ७५.७७
Low
CA$ ७२.००
Mkt. cap
७४.७४ करोड
Avg. vol.
८४८.००
Volume
४०३.००
52-wk high
CA$ १७०.००
52-wk low
CA$ ६८.०२
EPS
-CA$ २.९०
No. of employees
२६
News stories
From web sources and news partners
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc